Previous 10 | Next 10 |
Praxis Precision Medicines (PRAX) announces that it has commenced an underwritten public offering of 4M shares.Intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares.Praxis intends to use net proceeds, together with existing cash, for the advancem...
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today...
Praxis Precision Medicines (PRAX): Q1 GAAP EPS of -$0.71 beats by $0.03.Cash, cash equivalents and marketable securities of $270.8M.Press Release For further details see: Praxis Precision Medicines EPS beats by $0.03
Expands pipeline with new indications for PRAX-114 and PRAX-944 PRAX-114 Phase 2 trial for treatment of post-traumatic stress disorder to initiate in 2H21 PRAX-114 Phase 2 trial for treatment of essential tremor to initiate in 2H21 PRAX-944 Phase 2 trial for trea...
Gainers: Brooklyn ImmunoTherapeutics (BTX) +38%, Motus GI MOTS +32%, CryoLife (CRY) +16%, Mesoblast MESO +14%, Arcutis Biotherapeutics (ARQT) +10%.Losers: Ardelyx (ARDX) -13%, Pacific Biosciences of California (PACB) -13%, ALX Oncolo...
The FDA has granted Orphan Drug designation to Praxis Precision Medicines' (PRAX) PRAX-562 for the treatment of SCN2A development and epileptic encephalopathy (SCN2A-DEE).Earlier this month, PRAX-562 received the same designation for the treatment of SCN8A-DEE.The company plans to start a pha...
CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imba...
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, tod...
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, tod...
Gainers: Cinedigm (CIDM) +20%.Grupo Televisa (TV) +20%.GameStop (GME) +18%.Nurix Therapeutics (NRIX) +18%.Centennial Resource Development (CDEV) +17%.Regulus Therapeutics (RGLS) +16%.NexImmune (NEXI) +16%.UP Fintech (TIGR) +16%.Kymera Therapeutics (KYMR) +15%.Transocean (RIG) +...
News, Short Squeeze, Breakout and More Instantly...
Praxis Precision Medicines Inc. Company Name:
PRAX Stock Symbol:
NASDAQ Market:
Praxis Precision Medicines Inc. Website:
2024-07-26 13:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 13:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-20 14:30:05 ET Piper Sandler analyst issues OVERWEIGHT recommendation for PRAX on May 20, 2024 12:01PM ET. The previous analyst recommendation was Overweight. PRAX was trading at $44.93 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...